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ormal cells transform into cancer cells by the acquisition
of genetic aberrations in so called driver genes. In some
instances, the functional redundancy of mutations in
different genes results in a mutually exclusive mutation pattern
across tumor genomes because one alteration is sufficient to
activate the specific oncogenic pathway. Based on this assump-
tion, bioinformatic tools have been generated to search for
functional redundancy of mutated genes in larger cancer genome
datasets1,2.
In prostate cancer, recurrent gene fusions involving the ERG
transcription factor and point mutations in the ubiquitin ligase
adaptor SPOP are two truncal mutations that are mutually
exclusively distributed across tumor genomes (Fig. 1a and Sup-
plementary Fig. 1a)3–9. The underlying cause for this exquisite
pattern remains controversial. While earlier reports suggested a
functional redundancy between mutant SPOP and ERG based on
the finding that mutant SPOP stabilizes the ERG oncopro-
tein10,11, more recent studies challenge this view by showing
descriptive evidence for divergence in tumorigenesis3,12.
Here, we show that SPOP- and ERG-mutant cancer subtypes
are driven by antagonistic tumorigenic pathways involving fun-
damentally different roles of SPOP and androgen receptor sig-
naling levels. The divergence in tumorigenesis is associated with
specific susceptibilities to SPOP inhibition and perturbation in
the androgen receptor pathway.
Results
Activation of the ERG oncogene and missense mutation in
SPOP are synthetic sick. To shed light on these recurrent driver
genes’ functional relationship, we assessed the impact of SPOP
mutations and ERG activation on the cellular growth of mouse
prostate epithelial organoids. To do so, we first established and
validated the organoids by the presence of multilayered structure
with the expression of CK5 and CK8 in basal and luminal cells,
respectively (Supplementary Fig. 1b). In agreement with recent
reports, lentiviral-transduced point mutants of SPOP (SPOP-
Y87C, SPOP-W131G) or a truncated version of ERG, which
typically results from gene fusion with androgen-regulated genes
in prostate cancer (ΔERG, amino acids 33–486), promoted cell
growth (Fig. 1b and Supplementary Fig. 1c)13–16. While SPOP
mutant organoids displayed a round shape, ERG’s over-
expression gave rise to characteristic finger-like protrusions.
Surprisingly, the joint expression of both drivers considerably
diminished cell growth and reduced finger-like protrusions,
implying a synthetic sick relationship between the two genetic
alterations. Cytological follow-up analysis revealed reduced pro-
liferation evidenced by reduced Ki-67 and increased p16, P-HP1y
positivity, and vacuolization of the cytoplasm compatible with
senescence induction (Supplementary Fig. 1d).
We wondered if the observed synthetic sick relationship also
applied to established cancer cells from advanced, castration-
resistant metastatic disease. Forced expression of mutant SPOP
(SPOP-Y87C, SPOP-W131G) promoted 3D growth of ERG
fusion-negative LAPC-4 human prostate cancer cells (Supple-
mentary Fig. 2a). The oncogenic effect was paralleled by an
increase in the expression of the oncogenic transcription factors
MYC and HOXB13 and a decrease in the cell cycle inhibitor p21
as seen in an organoid line derived from SpopF133V-mutant
transgenic mice (Supplementary Fig. 2a, b)13. In contrast, we
observed the opposite phenotypic and molecular changes in
VCaP human prostate cancer cells harboring the recurrent
TMPRSS2-ERG fusion (Fig. 1c, d & Supplementary Fig. 2c, d). In
this setting, mutant SPOP (SPOP-Y87C, -F102C, -W131G,
-F133S) dramatically decreased cancer cells’ proliferation in
culture and the growth of xenograft tumor models in vivo.
Similarly, to the mouse prostate organoids, possible induction of
senescence was evidenced by increased senescence-associated β-
galactosidase (SA-β-gal)-positive cells and upregulation of p21
and GDF15 protein levels. In line with this, the transfer of
conditioned medium from VCaP cells expressing mutant SPOP
(SPOP-Y87C, SPOP-W131G) also reduced the proliferation of
parental VCaP cells, indicating a possible contribution of
senescence-associated secretory phenotype (SASP) and suggesting
that senescence could be one of the possible biological pathways
involved in the synthetic sick relationship (Fig. 1d and
Supplementary Fig. 2f, j).
Conversely, forced expression of ΔERG significantly reduced
the growth of SPOP-Y83C mutant LuCaP-147 patient-derived
xenograft (PDX) cancer cells in vivo and in culture (Fig. 1e and
Supplementary Fig. 3a, b)17, adding orthogonal support for a
synthetic sick relationship between mutant SPOP and ΔERG in
advanced prostate cancer. Besides, the over-expression of MYC
promoted cancer cell growth in both VCaP and LuCaP-147 cells
(Supplementary Fig. 3c, d). The latter finding may suggest that
the over-expression system per se is not the underlying cause of
the synthetic sick relationship mentioned above.
Next, we wondered if genetic or pharmacologic suppression of
ERG signaling may revert the growth suppressing function of
mutant SPOP in VCaP cells. Indeed, knockdown of ERG by
short-hairpin RNA interference decreased the growth of VCaP
control cells and of cells over-expressing wild-type SPOP, while it
promoted the growth of cells over-expressing SPOP-W131G
(Supplementary Fig. 3e). In addition, low doses of the ETS
inhibitor YK-4-279 promoted specifically the growth of VCaP
cells overexpressing mutant SPOP (Fig. 1f). We noted a similar
effect when VCaP cells were co-treated with a small molecule
inhibitor of SPOP (Supplementary Fig. 3f)18. In aggregate, the
data support an antagonistic relationship between oncogenic
activation of ERG and a loss of SPOP function in prostate
cancer cells.
Mutant SPOP-induced androgen receptor signaling antag-
onizes ERG activity. To assess the underlying molecular biology
of the antagonistic relationship between ERG-fused and SPOP-
mutants tumors, we interrogated the transcriptomes from the
TCGA cohort to nominate differences across these tumor sub-
types. Indeed, the unbiased principal component analysis (PCA)
revealed significant differences in the transcriptional output
(Fig. 2a). The differences were maintained in castration-resistant
prostate cancers (CRPC) from the (SU2C) cohort using a single-
sample gene-set enrichment analysis approach (Fig. 2b and
Supplementary Data 1). Furthermore, derived (PDX) models also
retained analog transcriptional differences, as demonstrated by
different behavior shown by SPOP-Mutant (LuCaP-78, −147)
and ERG-Fused (LuCaP-35, −23.1, VCaP cells) models (Fig. 2b
and Supplementary Data 1).
In SPOP-mutant prostate cancer, several dysregulated SPOP
substrates (e.g., NCOA3, TRIM24, BET proteins) have been
shown to boost the AR pathway leading ultimately to high levels
of AR target genes (Supplementary Fig. 4a)3,13,19–26. In contrast,
ERG-fused cancer cells typically express lower levels of AR target
genes as illustrated by the widely adopted AR score (Supplemen-
tary Fig. 4a)3. We further performed differential expression
analysis between the two tumor subtypes to get more insights into
this different behavior. Gene-set enrichment analysis resulted in a
clear upregulation of the canonical androgen response pathway in
SPOP-mutant vs. ERG-fused tumors, as defined by the respective
Hallmark gene-set, curated by the Molecular Signature Database
(MSigDB) (Supplementary Fig. 4b). In line with the divergence of
transcriptome profile identified in the PCA plot of Fig. 2a, a clear
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division between SPOP-mutant and ERG-fused tumors was also
reported in their respective cistrome counterpart25. By re-
analyzing ChIP-Seq data, we could determine that most
differentially bound regions between both tumor types are
characterized by increased AR-binding in SPOP-mutant tumors
(Fig. 2c and Supplementary Data 2).
Next, we analyzed the transcriptome changes of the VCaP cells
overexpressing SPOP mutants (SPOP-MTs; SPOP-Y87C, -F102C,
-F133S). The unbiased hallmark analysis showed a dramatic
increase in the androgen response, recapitulating the changes
identified in primary prostate cancer (Supplementary Figs. 4b and
5a, b). Based on these results, we posited that differential levels of
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androgen receptor (AR) signaling in SPOP-mutant vs. ERG-fused
cancers might be at the root of the incompatibility between the
driver events. Thus, we analyzed, in particular, AR- and ERG-
related transcription in VCaP cells and generated custom
signatures using ChIP-seq data and matched RNA-seq samples
(Supplementary Data 3)27. As expected, SPOP-MTs increased the
transcription of genes bound by AR and induced by its ligand
dihydrotestosterone (DHT), whereas genes bound by AR and
repressed by DHT were further reduced (Fig. 3a, Supplementary
Fig. 5c, and Supplementary Data 3–5). Remarkably, we observed
the opposite effect on genes bound only by ERG. Mutant SPOP
downregulated ERG-induced genes (e.g., MYC) and upregulated
ERG-repressed genes, respectively (Fig. 1d). In line with these
findings, gene ontology analysis of AR-ERG co-bound gene
signature in VCaP cells indicated that the most striking
transcriptional changes were linked to cellular differentiation
and cell cycle arrest that are directly induced by DHT and
repressed by ERG (e.g., HOXA genes, CDKN1A/p21, Fig. 1d,
Fig. 3b, and Supplementary Fig. 5d). To reduce the number of
genes falling within our custom signatures, we used a particularly
restrictive approach and considered co-bound only genes where
AR and ERG-binding sites overlapped for at least 1 bp. As a
result, some genes (e.g., CDKN1A/p21) that are bound both by
AR and ERG in their promoter region, but bindings of which do
not overlap are not included in this category despite being bona
fide co-bound targets.
The dramatic upregulation of this gene set was paralleled by
downregulation of cell cycle genes (e.g., E2F and MYC targets),
implying a direct link between the induction AR/ERG co-bound
genes, the repression of ERG targets, cell differentiation, and the
synthetic sick relationship of ERG and mutant SPOP (Fig. 1d,
Supplementary Fig. 5a–e, and Supplementary Data 6,7). The
relationship of AR- and ERG-related custom signatures to the
hallmark gene sets are highlighted in Fig. 3c in a two-dimensional
network. Moreover, independently generated signatures of
senescence-associated transcripts were enriched in VCaP over-
expressing SPOP mutants, further corroborating our data of a
senescence-induced cell cycle arrest (Supplementary Fig. 5f)28,29.
Fig. 1 Genetic alterations in SPOP and ERG are synthetic sick. a Distribution of genetic alterations in SPOP and ERG across 333 primary prostate cancers in
TCGA database3,8,9. b 3D growth of mouse prostate epithelial organoids derived from C57BL/6 mice over-expressing the indicated SPOP and ERG species
(bar represents 20 µm) (n= 3, technical replicates). Representative bright-field pictures and hematoxylin and eosin (H&E) stained sections are shown. c In
vivo growth of VCaP xenografts over-expressing the indicated SPOP species in immune-compromised mice (each group, n= 10). d Immunoblot of VCaP
cells overexpressing the indicated SPOP species and corresponding quantification of the indicated protein levels depicted as a heatmap. Protein expression
changes were normalized to β-ACTIN and Control cell line, (n= 2). e Tumor growth kinetics of xenografts established from LuCaP-147 PDX (SPOP-Y83C)
stably overexpressing ΔERG or Control vector (each group, n= 10). Corresponding immunoblot and quantification are depicted as a heatmap. Protein
expression changes were normalized to Vinculin (VCL) and Control cell line. f Dose–response curve of VCaP cells overexpressing the indicated SPOP
species and treated with the ETS-inhibitor YK-4-279. All error bars, mean+ s.e.m. P-values were determined by one-way ANOVA (b) or two-way ANOVA
(c, e, f) with multiple comparisons and adjusted using Benjamini–Hochberg post-test ****P < 0.0001. Molecular weights are indicated in kilodaltons (kDa).
Source data are provided as a Source Data File.
Fig. 2 Transcriptome analysis of primary prostate cancer patients reveals major differences between SPOP mutant and ERG-fused tumor subtypes.
a PCA-analysis based on RNA-Seq derived mRNA expression levels (TCGA cohort). ERG-fused (violet) and SPOP-mutant (green). Individuals were
annotated into subtypes as described in Material and Methods. b Boxplots representing the transcriptional activity of SPOP integrated-signature (see
Materials and Methods) applied to CRPC samples (SU2C-2019 cohort, left) and PDX-models. Scores are determined genes-signatures derived from
primary prostate tumors (TCGA-cohort). ERG-fused samples are depicted in violet, SPOP-mutant samples are depicted in green. Samples not harboring
SPOP mutations or ERG rearrangements are represented in gray. P-values were determined using Wilcoxon rank sum test and adjusted for multiple testing.
Individual. (Boxplots, ERG: max=0.22; min=−0.75; center=−0.31; Q2 (25%)=−0.47; Q3 (75%)=−0.13, OTHER: max= 0.88; min=−0.55; center=
−0.03; Q2 (25%)=−0.20; Q3 (75%)= 0.12, SPOP: max= 0.79; min=−0.02; center= 0.50; Q2 (25%)= 0.19; Q3 (75%)= 0.64.) c Boxplots depicting
the number of normalized reads per binding site across all the differentially bound (DB) regions resulting from the comparison between ERG-fused (violet)
and SPOP-mutant (green) samples. Analysis was restricted to DB regions showing an adjusted P-value (FDR) lower than 0.05 (as determined by DiffBind/
DESeq2 pipeline). Subsequently, significance between ERG and SPOP subgroups was assessed using Wilcoxon rank sum test. (Boxplots, ERG: max= 8.14;
min=−0.85; center= 1.51; Q2 (25%)= 0.74; Q3 (75%)= 2.39, SPOP: max= 7.03; min=−1.07; center= 2.76; Q2 (25%)= 2.11; Q3 (75%)= 3.48).
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Conversely, we assessed the consequence of ERG overexpression
in LNCaP cells under low DHT levels where mutant SPOP triggers
AR signaling and tumor growth (Supplementary Fig. 6a, b and
Supplementary Data 8 and 9)19,23. Over-expression of ΔERG in this
setting robustly reverted the induction of signatures related to cell
proliferation (e.g., E2F and MYC targets) and AR signaling. Taken
together, the data imply a mutual incompatibility of mutant SPOP-
induced AR signaling and the function of the ERG oncogene.
Next, we verified if corresponding transcriptional changes were
found in clinical tissue samples. Indeed, ERG-regulated genes
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culled from VCaP cells were upregulated in ERG-fused and
downregulated in SPOP-mutant primary tumors (Fig. 3d, Supple-
mentary Fig. 6c, and Supplementary Data 10, 11)3. Notably, the
most striking changes between the two groups were found again in
the AR/ERG co-bound gene set in primary prostate cancers
(Supplementary Fig. 6d and Supplementary Data 12, 13)3,6. The
results underscore both the relevance of our cell culture-based data
and highlight the transcriptional differences among ERG- and
SPOP-driven tumors.
ZMYND11 is a de novo SPOP substrate. Using tandem mass tag
(TMT)-based quantitative mass spectrometry, we set out to search
for SPOP substrates that may influence the activity of AR and
ERG and thereby may cause to the synthetic sick relationship
between mutant SPOP and ERG in VCaP cells overexpressing
mutant SPOP (SPOP-MTs; SPOP-Y87C, -F102C, -W131G, Fig. 4a
and Supplementary Data 14). As recurrent loss-of-function SPOP
mutants impair substrate ubiquitylation and proteasomal degra-
dation, we searched for proteins the expression levels of which
increase without a concomitant increase in mRNA levels (Fig. 4b,
Supplementary Fig. 7a, and Supplementary Data 15). Overall, we
noted a strong correlation of protein with mRNA expression
changes with consistent changes of our AR and ERG custom
signatures at the protein level (Fig. 4b and Supplementary Fig. 7b,
c). In addition, we found a marked upregulation of the known
SPOP substrate and AR activator TRIM24 at the protein level
(Figs. 1d and 4a; Supplementary Data 14)22,23 and subsequently
assessed if TRIM24 and more generally AR is implicated in the
synthetic sick relationship between mutant SPOP and ERG.
Indeed, knockdown of TRIM24 by two short-hairpin RNAs par-
tially reverted the growth inhibition mediated by mutant-SPOP in
VCaP cells and reduced AR signaling (Supplementary Fig. 7d–f),
while over-expression of AR was sufficient to decrease cellular
growth (Supplementary Fig. 7g, h).
The most striking upregulation was noted for the bromodo-
main histone reader ZMYND11 (Fig. 4b). In line with a SPOP
substrate, wild type SPOP bound and decreased the expression of
HA-ZYMND11 in a proteasome-dependent manner (Fig. 4c, d).
We found two degron sequences that were required for efficient
SPOP-mediated ubiquitylation and protein degradation (Fig. 4e±g
and Supplementary Fig. 8a.). As expected, SPOP mutants failed
to bind and adequately ubiquitylate HA-ZMNYD11-WT
(Fig. 4h–j)10,11,20–22,24–26. Finally, we confirmed that the expres-
sion of mutant SPOP prolonged the half-life of endogenous
ZMYND11 in VCaP cells and upregulated ZMYND11 expression
in other prostate cancer cells (Fig. 4k and Supplementary Fig. 8b).
ZMYND11 induces AR signaling pathway and represses ERG
activity. Next, we assessed if ZMYND11 protein upregulation
also contributed to the synthetic sick relationship. In support,
forced expression of the degron-deficient variants of ZMYND11
(HA-ZMYND11-DMT1/DMT2) was sufficient to diminish the
growth of VCaP cells (Fig. 5a, b and Supplementary Fig. 8c),
while knockdown of ZMYND11 partially reverted the growth
inhibition mediated by mutant SPOP (Fig. 5c).
We postulated that ZMYND11 upregulation could contribute
to the synthetic sick relationship by repressing the ERG
oncogene’s transcriptional activity or enhancing AR signaling.
To this end, expression changes induced by HA-ZMYND11-
DMT2 largely overlapped with genes perturbed by mutant SPOP
while the opposite was noted when ZMYND11 expression was
reduced by RNA interference (Fig. 5d, Supplementary Fig. 8d,
and Supplementary Data 16). In comparison to mutant SPOP,
AR and ERG target genes were similarly dysregulated by HA-
ZMYND11-DMT2 (Fig. 5e and Supplementary Data 17, 18). As
the PWWP domain of ZMYND11 has been involved in the
regulation of transcription through its ability to bind H3K36me3
histone marks30, we tested this domain’s contribution to the
overall transcriptional output. Indeed, the PCA of VCaP cells
over-expressing either HA-ZMYND11-DMT2 or a PWWP
domain deficient mutant (W294A) revealed a major contribution
of this domain to the ZMYND11 induced transcriptional changes
(Supplementary Fig. 8e).
Subsequently, we mapped the genomic occupancy of
ZMYND11 in VCaP cells expressing the SPOP-Y87C mutant
by chromatin immunoprecipitation sequencing (ChIP-seq) and
found an enrichment of ZMYND11-binding sites at promoter
regions controlling ERG-induced genes (e.g., MYC,) and AR/ERG
co-bound genes (e.g., p21/CDKN1A) (Fig. 5f, g, Supplementary
Fig. 9a–e, and Supplementary Data 19–22). The data imply a
critical enhancer function of ZMYND11 in boosting AR signaling
and repressing ERG signaling downstream of mutant SPOP.
Wild type SPOP is required for ERG oncogenic function. We
reasoned that ERG-driven tumors might require wild type SPOP
to degrade ZMYND11 and unlock ERG’s oncogenic function. In
support, over-expression of wild type SPOP increased the 3D
growth of mouse prostate epithelial organoids and VCaP cells
only when ERG was over-expressed (Fig. 1b, Supplementary
Figs. 2c and 10a, b). Remarkably, ERG-fused human tumor tis-
sues also displayed the highest SPOP mRNAs levels (Fig. 6a).
Thus, we wondered if ERG itself may directly upregulate SPOP
transcription to support its own oncogenic activity. Indeed,
mining ERG ChIP-seq data in VCaP cells revealed ERG bindings
sites in the promoter region of SPOP (Supplementary Fig. 10c).
Moreover, knockdown of ERG reduced SPOP protein levels in
VCaP cells, while forced expression of a ΔERG led to the upre-
gulation of SPOP mRNA and protein levels in PC3 cells (Fig. 6b,
Supplementary Figs. 3e and 10d).
Fig. 3 Mutant SPOP-induced, androgen receptor signaling, antagonizes ERG activity. a Gene-set enrichment analysis of VCaP cells overexpressing SPOP
mutant (SPOP-MTs; SPOP-Y87C, -F102C, -W131G) vs. SPOP-wild type (-WT), based on RNA-seq data. Experiments were performed using three replicates
for each condition. Enrichments are determined on custom gene-sets of direct androgen receptor (AR) and ERG target genes (Supplemental Dataset 1).
Enrichments and FDR-adjusted P-values are computed with Camera (pre-ranked) b Venn Diagram and heatmap depicting the expression of genes included
in the custom gene-set of AR/ERG co-bound genes that are repressed by ERG and induced by DHT in VCaP cells overexpressing SPOP-MTs (SPOP-Y87C,
F102C, W131G), SPOP-WT and vector Control. Genes (rows) and samples (columns) were clustered using Euclidean distance. Gene expression values
were normalized using variance stabilizing transformation (vst) and subsequently scaled and centered by row prior of clustering. Columns represent the
average expression of three replicates for each condition. c Two-dimensional network representing overlaps between the ten most significantly enriched
Hallmark and custom gene-sets, identified when comparing SPOP-MTs (SPOP-Y87C, F102C, W131G) to SPOP-wild type (-WT) overexpressing VCaP cells.
The thickness of edges is proportional to the significance of the overlap of the connected nodes measured by the Fisher test. Only edges with FDR value
<0.05 are shown. The size of nodes is proportional to gene-set enrichment significance and equals to −10 x log10 (FDR). d Heatmap representing gene-set
activity stratified according to tumor subtype, derived from TCGA cohort. For each tumor group, the average value of single-sample GSEA scores was
considered. Values were scaled and referenced to samples that did not harbor any ETS-fusion (ERG, ETV1, and ETV4) or point mutations in SPOP3.
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We then asked if the elevated SPOP levels in the context of
forced ΔERG expression have a functional impact on the
oncogenic activity of ΔERG in the androgen-independent PC3
cells, in which ERG promotes tumor cell invasion31. Indeed, the
reduction of SPOP levels by RNA interference reduced the ability
of ΔERG to invade into Matrigel (Fig. 6c). Similarly, knockdown
of SPOP in VCaP cells reduced cell growth in 3D cell culture and
impaired ERG-mediated gene transcription (Supplementary
Fig. 10e, f and Supplementary Data 23 and 24). In accordance
with the ability of mutant SPOP to repress the function of
endogenous wild type SPOP in a dominant-negative manner, the
over-expression of mutant SPOP (SPOP-Y87C, -F102C, -W131G,
-F133S) phenocopied the effect of SPOP knockdown on ERG-
mediated invasion in PC3 cells (Supplementary Fig. 10g, h). In
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agreement with the established repressive function of ZMYND11
on ERG, we found that over-expression of HA-ZMNYD11-DM2
was sufficient to repress ERG-induced invasion and established
target genes in PC3 cells (Fig. 6d, e). Taken together, the data
imply the existence of a positive feed-forward loop, in which
ΔERG promotes the expression of SPOP to sustain its oncogenic
activity.
ERG and mutant SPOP trigger different responses to ther-
apeutic interventions. Based on the differences mentioned above
in tumorigenesis, we speculated that ERG or mutant SPOP could
also trigger different therapeutic responses. In light of the
dependency of ERG-driven tumors on wild type SPOP function,
we hypothesized that ERG-fusion-positive cells might be parti-
cularly sensitive to pharmacological inhibition of SPOP. We
analyzed the response of the SPOP small molecule inhibitor
compound 6b (SPOP-i) in ERG-fused, SPOP mutant, and other
prostate cancer cell lines and patient-derived xenograft models
(PDX)18. The SPOP inhibitor increased the protein but not the
mRNA levels of established SPOP substrates and ZMNYD11,
while the related inactive analog compound 6c did not (Supple-
mentary Fig. 11a–c). The latter did also not exert any activity in
3D culture models (Supplementary Fig. 11d). In agreement with
our previous results, we found that ERG-fused cells (VCaP,
LuCaP-23.1, −35) were more sensitive to SPOP-i than ERG-
negative cells (22Rv1, LNCaP, PC3), while SPOP mutant cells
(LuCaP-78, −147) were particularly insensitive in 3D culture
models and in xenograft tumor models in vivo (Fig. 7a–f and
Supplementary Fig. 11e). We further validated our results in the
mouse prostate epithelial organoids and confirmed the increased
sensitivity of ΔERG-expressing cells to SPOP inhibition in this
isogenic system (Fig. 7g).
Given the notion that wild type SPOP dampens AR function in
the context of ERG to sustain tumor growth, we asked if VCaP
cells are particularly susceptible to increased DHT levels. Indeed,
exposure to a high-dose of testosterone in vivo or DHT in vitro
induced similar molecular changes as for the over-expression of
mutant SPOP and greatly suppressed the growth of ERG-fusion-
positive cells but not of SPOP mutant cells in vitro and in vivo
(Figs. 1c and 8a–f; Supplementary Fig. 12a–e and Supplementary
Data 25 and 26). Moreover, signatures of senescence-associated
transcripts were also enriched in VCaP cells upon treatment with
DHT, further corroborating our data of a senescence-induced cell
cycle arrest (Supplementary Fig. 12f). Strikingly, the sensitivity to
SPOP-i and to high testosterone in vivo correlated well with ERG
protein expression levels in the respective ERG-fusion-positive
cell line and PDX model (Fig. 8g, h). The data suggest a
therapeutic opportunity for SPOP inhibition or high-dose
androgen therapy in prostate cancers that express high levels of
ERG.
Conversely, and because SPOP mutant cancers are driven
predominantly by androgen signaling and consequently display
high-level activation of AR-related transcripts in human tumor
tissues, we speculated that these tumors might be particularly
susceptible to androgen deprivation or antiandrogen therapies
(ADT) (Supplementary Fig. 4c). Indeed, the prevalence of SPOP
mutations in primary tumors -and tumors that had progressed
after initial surgery or radiotherapy- is consistently higher as
compared to tumors that had become resistant to subsequent
ADT (also referred to as castration-resistant prostate cancer,
CRPC, Supplementary Fig. 13a). In line with the notion that this
difference may be related to a better response of SPOP mutant
tumors to ADT, SPOP mutant tumors display a trend towards
better overall survival despite progressing faster after initial
therapy (Fig. 9a, b). To functionally analyze androgen deprivation
or the antiandrogen enzalutamide response, we chose to
ectopically express different SPOP variants and ΔERG in the
androgen-dependent human LAPC4 prostate cancer cells that are
wild-type for both driver genes. In accordance with the clinical
observation, the presence of mutant SPOP (SPOP-Y87C, SPOP-
W131G) rendered LAPC4 cells more susceptible to either ADT or
enzalutamide in comparison to cells expressing control vector
(Fig. 9c and Supplementary Fig. 13b).
In contrast, ΔERG rendered the same cells more resistant to
enzalutamide. In line with the previous findings in VCaP and
LuCaP-147 cells, ΔERG expression rendered LAPC4 cells
susceptible to high levels of DHT, while mutant SPOP had the
opposite effect (Supplementary Fig. 13b). Taken together, the
different responses to established and experimental therapeutic
modalities observed between mutant SPOP and ERG add further
credence to their divergent roles of the AR pathway related to
tumorigenesis.
Discussion
Although multiple studies over recent years have uncovered dif-
ferent genetically-defined subtypes of primary prostate cancer,
Fig. 4 ZMYND11 is a de novo SPOP substrate. a Schematic illustration showing the design of the proteomics experiments. Tandem Mass Tag (TMT)-
based quantitative mass spectrometry (n= 2) was used in VCaP cells overexpressing Control vector (Control), SPOP-WT, or three different SPOP mutants
(SPOP-Y87C, SPOP-F102C, and SPOP-W131G). b Scatter plot comparing transcriptomic and proteomic derived fold changes resulting from the comparison
between SPOP-MTs (average across SPOP-Y87C, -F102C, -W131G) and SPOP-WT VCaP cells. (n= 3 for transcriptome, n= 2 for proteome). Genes
belonging to DHT-Induced/ERG-Repressed gene-signature (AR+ ERG co-bound) are highlighted in red. TRIM24 and ZMYND11 are the most upregulated
proteins without changes at mRNA levels and are highlighted in green. CDKN1A (p21) upregulated at both mRNA and protein levels, and MYC
downregulated at both mRNA and protein levels are highlighted in black. c Over-expression of HA-ZMYND11 and SPOP-WT in 293T cells and subsequent
expression analysis of the indicated proteins by immunoblotting (n= 2). d Whole-cell extracts (WCE) of 293T cells over-expressing HA-ZMYND11-WT
and different SPOP species and corresponding anti-HA-immunoprecipitation (HA-IP). Expression of the indicated proteins was analyzed by
immunoblotting (n= 1). e Domain structure of ZMYND11 with indicated SPOP-degron and ubiquitin sites. f Forced expression of SPOP-WT together with
HA-ZMYND11-WT or two degron-deficient mutants (DMT1 & DMT2) in 293T cells (n= 1). g In vivo ubiquitylation assay of HA-ZMYND11 in 293T cells.
Cells were transiently transfected with the indicated constructs, and histidine-tagged (his-tag), ubiquitylated proteins were pulled down using nickel beads.
Ubiquitylated HA-tagged ZMYND11 was detected by immunoblotting (n= 1). h Over-expression of HA-ZMYND11 and SPOP-Y87C in 293T cells and
subsequent expression analysis of the indicated proteins by immunoblotting after proteasomal inhibition with MG132. i Whole-cell extracts (WCE) and
corresponding anti-HA-immunoprecipitation (HA-IP) of 293T cells over-expressing HA-ZMYND11-WT and different SPOP-MTs species as indicated.
Expression of the indicated proteins was analyzed by immunoblotting (n= 1). j In vivo ubiquitylation assay of HA-ZMYND11 in 293T cells. Cells were
transiently transfected with the indicated constructs and histidine-tagged (His-tag); ubiquitylated proteins were pulled down using nickel beads.
Ubiquitylated HA-tagged ZMYND11 was detected by immunoblotting (n= 1). k Immunoblots of indicated proteins in VCaP, LNCaP, and LAPC4 human
prostate cancer cells overexpressing the indicated SPOP species. Molecular weights are indicated in kilodaltons (kDa) (n= 3). Source data are provided as
a Source Data File.
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their biological understanding and therapeutic implications
remain a largely unexplored territory. Here, we report two dia-
metrically different paths toward tumorigenesis triggered by
either highly recurrent missense mutation in SPOP or gene fusion
involving the ERG oncogene. Importantly, wild-type SPOP
emerges as a critical component that enforces oncogenic ERG
signaling in part through dampening AR activity, while mutant
SPOP drives tumorigenesis through activation of AR signaling.
Moreover, several studies have previously highlighted the
importance of AR target genes in the context of SPOP mutants
Fig. 5 ZMYND11 induces AR signaling pathway and represses ERG activity. a, b Immunoblot of indicated proteins (n= 2) (a) and corresponding 2D
proliferation assay (b) of VCaP cancer cells overexpressing HA-ZMNYD11-WT and derived degron-deficient mutants (DMT1/2) (n= 3). Correlation
between cell viability and ZMYND11 protein expression changes (Prot. Exp. Changes), as quantified by immunoblot in the same cell lines. P-values were
calculated using the Pearson rank correlation. c Fold-change cell viability of VCaP cancer cells overexpressing the indicated SPOP species with and without
ZMYND11 knockdown using two different short-hairpin RNAs, at day 16 (n= 3) one-way ANOVA with multiple comparisons and adjusted using
Benjamini–Hochberg post-test. The protein expression of the indicated proteins was analyzed by immunoblotting. d Chord-diagram of transcriptionally
regulated genes by either SPOP-MTs or HA-ZMYND11-DMT2 in VCaP cells (FDR < 0.05). Strings, whose thickness is proportional to the number of shared
elements, represent common genes between sets. e Gene-set enrichment analysis of VCaP cell overexpressing HA-ZMYND11-DMT2 compared to
Control, based on RNA-seq data. Enrichments are performed on custom gene-sets of direct androgen receptor (AR) and ERG target genes. FDR-adjusted P-
values are computed with Camera (pre-ranked). f Heatmap of ChIP-seq signals around TSS regions (+/−4 kb) at which ZMYND11 bindings were identified
by peak calling procedure (Macs2) in VCaP cells overexpressing the indication constructs. g IGV-derived screenshots representing loglikelihood ratio of
ZMYND11 bindings in mutant SPOP (SPOP-Y87C) vs. wild-type SPOP over-expressing VCaP cells. Reported areMYC (up) and CDKN1A (bottom). All error
bars, mean ± s.e.m. P-values were determined by two-way ANOVA (b Molecular weights are indicated in kilodaltons (kDa). Source data are provided as a
Source Data File.
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and ERG-positive tumors19,32,33. Based on the incompatibility
between the two tumor subtypes, our work enabled the devel-
opment of specific custom signatures related to AR and ERG
transcript that are necessary to drive proliferation and tumor-
igenesis in the context of ERG-positive and SPOP-mutants
tumors. In addition, we show that the bromodomain histone
reader ZMYND11 is a SPOP substrate implicated downstream of
SPOP in the opposing regulation of the ERG and AR pathway in
the two tumor subtypes (Fig. 10). The AR and ERG pathways
have been previously reported to have a partially antagonistic
relationship33,34, further corroborating our findings.
As activation of the androgen receptor by androgens represents
a key lineage specific oncogenic pathway in prostate cancer,
androgen deprivation/antagonization therapies (ADT) remain the
uniform treatment modality up to this very day. That said, the
responses to ADT are highly variable and may last from a few
weeks up to many years. Here, we provide functional evidence
that pre-existing prostate cancer founder mutations influence the
treatment response. Most notably, SPOP mutations promote
susceptibility to androgen deprivation therapies. In agreement
with our findings, earlier reports have shown the under-
representation of SPOP mutant tumors in cohorts of castration-
resistant disease and a more favorable response to the abiraterone
and enzalutamide35,36.
Conversely, we show that the ERG oncogene’s presence
increases the susceptibility of tumor cells to high-dose androgen
therapy, while cells expressing mutant SPOP remain largely
unaffected. This is of clinical interest because testosterone treat-
ment of patients with the advanced castration-resistant disease
has recently shown to trigger anti-tumor responses in around
one-third of the patients37. It is tempting to speculate that these
insights may help to discern responders from non-responders.
In addition, we provide evidence that the antagonistic rela-
tionship between mutant SPOP and ERG may be used towards
the development of new therapeutic avenues. More specifically,
we show that ERG-driven cancer cells are particularly sensitive to
the inhibition of wild-type SPOP using recently developed small
molecule inhibitors18. Our preclinical data suggest that SPOP
inhibition may be effective in clinical settings where ERG is
robustly expressed (e.g., neo-adjuvant setting or early metastatic
disease).
Our results generally identify another paradigm for antagonistic
driver genes in prostate cancer that has recently emerged for other
cancer types38–40. In analogy to prostate cancer, truncal point
mutations in DNMT3A and gene fusions in PML-RARA are
mutually exclusive drivers in acute myeloid leukemia (AML).
Similar to SPOP, intact DNMT3A has been found to be critical for
PML-RARA-driven leukemia (Supplementary Fig. 14a, b)41,42.
Fig. 6 SPOP-WT is an ERG target gene and required for ERG-mediated cell invasion. a SPOP mRNA expression levels in 333 primary prostate cancer
tissues stratified according to the indicated driver mutations3. Error bars, mean ± s.d. b SPOP mRNA and protein levels in response to forced expression of
ΔERG in PC3 prostate cancer cells by qPCR and immunoblotting, respectively. Error bars, mean+ s.e.m. (n= 3). P-values were determined by unpaired,
two-tailed Student’s t-test. Control vs. ΔERG for SPOP expression levels. Control vs. ΔERG for ERG expression levels. c Transwell Matrigel invasion assay of
PC3 cells with forced expression of ΔERG and knockdown of SPOP using two different short-hairpin RNAs. Protein expression of the indicated proteins was
assessed in parallel by immunoblotting. Error bars, mean ± s.e.m. (n= 3) (bar represents 400 µm). d Transwell Matrigel invasion assay of PC3 cells with
forced expression of ΔERG and HA-ZMYND11-DMT2 and corresponding immunoblot analysis. Error bars, mean ± s.e.m. (n= 3) (bar represents 400 µm).
e Analysis of the ΔERG- and HA-ZMYND11-DMT2-induced transcriptional changes in the ERG target genes PLAU and PLAT. All error bars, mean ± s.e.m. P-
values were determined by one-way ANOVA with multiple comparisons and adjusted using Benjamini–Hochberg post-test (a, c, d, e). NS, not significant.
Molecular weights are indicated in kilodaltons (kDa). Source data are provided as a Source Data File.
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Importantly, we demonstrate here for prostate cancer that the
concept of antagonistic driver genes can be exploited to identify
therapeutic opportunities.
Methods
Cell culture, transfection, and infection. VCaP, LNCaP, PC3, 22Rv1, HEK293
cells were purchased from ATCC. LAPC-4 was a gift from Prof. Helmut Klocker.
VCaP and HEK293 were grown in DMEM with Glutamax (Gibco); LNCaP, PC3,
22Rv1, LAPC-4 in RPMI medium (Gibco); all were supplemented with 10% full
bovine serum (FBS; Invitrogen), or 10% charcoal-stripped serum (CSS; One-Shot
Fetal Bovine Serum, Charcoal Stripped, Gibco) for androgen deprivation therapy
response, and 1% Penicillin/Streptomycin. LuCaP-147 were grown in StemPro
medium (hESC SFM StemPro, Gibco) with regular supplements. All cells were
incubated at 37 °C and 5% CO2 and routinely tested for mycoplasma
contamination.
For stable knockdown experiments, cells were infected with pLKO-1 vectors
(Sigma) and the following clones were used; SPOP: TRCN0000140431 (shSPOP_1)
and TRCN000013911 (shSPOP_2); TRIM24: TRCN000021262 (shTRIM24_1) and
TRCN0000195528 (shTRIM24_2); ERG: TRCN0000429354 (shERG_1) and
TRCN0000432394 (shERG_2); ZMYND11: TRCN0000275479 (shZMYND11_1)
and TRCN0000275542 (shZMYND11_2). After infection, cells were selected in the
presence of puromycin (2 μg/ml).
For SPOP, ΔERG, HA-ZMYND11-WT, HA-ZMYND11-DMT1, HA-
ZMYND11-DMT2, MYC, and AR over-expression a derivate of the pLX304 vector
was used throughout in which the CMV promoter has been exchanged to a PGK
promoter, and the blasticidin cassette left unchanged (ΔERG constructs) or
exchanged by a puromycin resistance cassette (SPOP constructs) (pLX_TRC_307,
available at Addgene as Plasmid 41392, pCW107). All ORFs were cloned into
pLX_TRC_307 using Nhe1 and Mlu1. Tumors from PDX LuCaP-78, −147, −35,
−23.1 were collected, dissociated and cultured as previously described43. Briefly,
PDX tumors were collected in phosphate-buffered saline (PBS) and dissociated on
a petri dish in Advanced DMEM (Hepes, Glutamine, Pen/Strep) with 200 U/ml of
collagenase Type I (Cat#SCR103) followed by 45 min of incubation at 37 °C. Next,
the cell suspension was filtered using a cell strainer 100 µM and centrifuged at
300 × g for 5 min. Red blood lysis buffer (Cat# 11814389001) was added to the
solution for 5 min to eliminate red blood cells. Finally, the dissociated tumor was
resuspended in PBS and used accordingly for cell culture.
Chemicals. MG-132 (M7449) and Cycloheximide (CHX, C4859) were purchased
from Sigma and used at 20 μM and 100 μg/ml in all experiments, respectively.
SPOP inhibitor (SPOP-i, compound 6b) and its inactive analog (compound 6c),
Fig. 7 ERG-positive tumor cells are particularly sensitive to SPOP inhibition. a SPOP inhibitor (SPOP-i, compound 6b) mediated 3D growth inhibition in
methylcellulose in the indicated prostate cancer cell lines. b Tumor growth kinetics with (n= 10) or without (vehicle; n= 10) SPOP-i treatment in
xenografts established from LuCaP-147 (SPOP-Y83C) PDX cells. c Tumor growth kinetics with (n= 4) or without (vehicle; n= 4) SPOP-i treatment in
xenografts established from LuCaP-78 (SPOP-W131G) PDX cells. d Tumor growth kinetics with (n= 11) or without (vehicle; n= 11) SPOP-i treatment in
xenografts established from VCaP. e Tumor growth kinetics with (n= 6) or without (vehicle; n= 8) SPOP-i treatment in LuCaP-23.1 (ERG-positive)
f Tumor growth kinetics with (n= 8) or without (vehicle; n= 10) SPOP-i treatment in LuCaP-35 (ERG-positive) PDX PDX. All SPOP-i treatment initiated
when tumors reached an average of 100mm3. g Dose–response curves to SPOP-i treatment of Mouse Prostate Organoids overexpressing ΔERG, SPOP-
Y87C and Control vector. All error bars, mean+ s.e.m. P-values were determined by two-way ANOVA with multiple comparisons and adjusted using Šidák
post-test. NS, not significant. ****P < 0.0001. Molecular weights are indicated in kilodaltons (kDa). Source data are provided as a Source Data File.
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Fig. 8 ERG and mutant SPOP trigger different responses to therapeutic interventions. a Dose–response curve to DHT treatment of VCaP, LuCaP-35,
LuCaP-78, and LuCaP-147 PDX cancer cells. Before DHT treatment, PDX were grown in standard media without DHT. VCaP were starved for 24 h in CSS
medium (RPMI+ 10% charcoal-stripped serum). Cell viability was assessed after 2 weeks. b Tumor growth kinetics with (n= 10) or without (vehicle; n=
10) testosterone treatment in xenografts established from LuCaP-147 (SPOP-Y83C). c Tumor growth kinetics with (n= 4) or without (vehicle; n= 4)
testosterone treatment in xenografts established from LuCaP-78 (SPOP-W131G) cells. d Tumor growth kinetics with (n= 6) or without (vehicle; n= 10)
testosterone treatment in xenografts established from VCaP (ERG-positive) cells. e Tumor growth kinetics with (n= 12) or without (vehicle; n= 12)
testosterone treatment in xenografts established from LuCaP-23.1 (ERG-positive) cells. f Tumor growth kinetics with (n= 10) or without (vehicle; n= 10)
testosterone treatment in xenografts established from LuCaP-35 (ERG-positive) cells. g Sensitivity to Testosterone and SPOP-i treatment in xenograft and
PDX models. LuCaP-23.1, LuCaP-35 and VCaP are ERG-positive cancer cells. LuCaP-147 and LuCaP-78 are SPOP mutant cancer cells (respectively SPOP-
Y83C and SPOP-W131G). Growth inhibition is calculated using the last tumor measurements as shown in b-f and Fig. 7b–f. h Correlation of sensitivity to
SPOP-i or testosterone treatment shown in Extended Data Figs. 8f–j and 9e–i, with ERG protein levels, as quantified by immunoblot, in PDX models and
xenografts. P-values were calculated using Pearson rank correlation. Corresponding immunoblot and quantification of AR and ERG protein levels depicted
as a heatmap. Protein expression changes were normalized to GAPDH and LuCaP-78. All error bars, mean+ s.e.m. P-values were determined by two-way
ANOVA with multiple comparisons and adjusted using Benjamini–Hochberg post-test (b–e) or by unpaired, two-tailed Student’s t-test (g), NS, not
significant. Molecular weights are indicated in kilodaltons (kDa). Source data are provided as a Source Data File.
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were provided by the laboratory of C. Yang (State Key Laboratory of Drug
Research, Shanghai Institute of Materia Medica). DHT (5α-Dihydrotestosterone)
was purchased from Sigma (D-073), MDV3100 (Enzalutamide) was purchased
from APExBIO (A3003). YK-4-279 (ETS inhibitor) was purchased from Sell-
eckchem. All chemicals were used at the indicated concentration.
Dose–response curves and cell-growth assays. Cells were seeded (between 1 ×
103 and 1 × 104 per well) in a 96-well plate. Cells were subsequently treated with
serial dilutions of DHT (in 10% CSS medium), or enzalutamide, SPOP inhibitor,
ETS inhibitor to determine dose–response curves or were left untreated for cell-
growth assays. Proliferation at corresponding time points was assessed by MTT
(Methylthiazolyldiphenyl-tetrazolium bromide) assay according to the manu-
facturer’s recommendations (Sigma). For each time point, absorbance (OD, 590
nm) was measured in a microplate reader.
SA-β-galactosidase staining of VCaP cells. Senescence-associated-β-
galactosidase (SA–β-gal) staining was performed using the Senescence β-
Galactosidase Staining Kit (Cell Signaling, #9860) following the manufacturer’s
instructions. To avoid false-positive staining, we adapted the β-Galactosidase
Staining Solution to pH 7. Cells incubated with glycerol 70% were observed under a
bright-field microscope.
Matrigel invasion assay. Invasion assay was performed as previously described44.
Briefly, an equal number of PC3 cells were seeded into 10 cm dishes and starved
with a medium without fetal bovine serum for 24 h; subsequently, 1 × 105 cells were
resuspended in 100 µl of starved medium and seeded onto the basement of a
Boyden chamber (CLS3422; Sigma) coated with Matrigel. RPMI with 10% fetal
bovine serum was added to the lower chamber. After 48 h, invaded cells were fixed
with 10% formalin and stained with crystal violet. Absorbance was measured at
560 nm.
Clonogenic assay in methylcellulose. Cells were seeded (between 5 × 103 and 1 ×
104) in methylcellulose (Methocult H4100, StemCell Technologies) in triplicate.
Cells were left untreated for cell-growth assay. For SPOP inhibitor assay, cells were
treated with vehicle (0.1% DMSO) or drug (SPOP-i) at the corresponding con-
centration. For androgen therapy, cells were treated with vehicle (0.01% Methanol)
or DHT at the corresponding concentration. Cells were incubated at 37 °C and 5%
CO2 for 7–28 days, and colonies were stained with MTT solution at 37 °C over-
night, and absorbance (OD, 590 nm) was measured in a microplate reader.
Mouse prostate organoid generation and experiments. Prostate tissue was
extracted from euthanized mice, digested, and seeded in Matrigel as previously
described45. Briefly, the urogenital system was isolated from the mouse. Seminal
vesicles, vas deferens, urethra, and the bladder were removed. The clean prostate
was minced in small pieces (1 mm3) and digested in 5 mg/ml of collagenase type II
(Collagenase Type II nr. 9001-12-1, gibco) with 10 µM of Y-27631 dihydrochloride
for 1–2 h at 37 °C on a moving platform. Later, the minced prostate was centrifuged
at 150 × g for 5 min, and the pellet was resuspended in TrypLE (gibco TrypLE
Fig. 9 SPOPmutant tumors are particularly susceptible to androgen deprivation therapies (ADT). a Progression-free survival of prostate cancer patients
derived from the TCGA-cohort. Curves representing TMPRSS2-ERG rearranged, and SPOP-mutant patients are indicated in violet and green, respectively.
The area around the curves represents 80% confidence interval. The bar plot in the lower left corner indicates the percentage of SPOP-mutant tumors
within all patients diagnosed with prostate cancer (DIAG) and within the individuals who developed a progression of the disease (PROG). P-values for
Kaplan–Meier curves were determined using the log-rank test (P= 0.115). b Overall survival of prostate cancer patients derived from the MSK-IMPACT
cohort. Curves representing TMPRSS2-ERG rearranged, and SPOP-mutant patients are indicated in violet and green, respectively. The area around the
curves represents 80% confidence interval. The bar plot in the lower left corner indicates the percentage of SPOP-mutant tumors within all patients who
were diagnosed with prostate cancer (DIAG), within individuals who developed a metastatic progression of the disease (PROG), and within individuals who
developed castration-resistant prostate cancer (CRPC). P-values for Kaplan–Meier curves were determined using the log-rank test. (P= 0.247).
c Enzalutamide sensitivity of LAPC4 cells overexpressing ΔERG or SPOP mutant species (Y87C, W131G). All error bars, mean+ s.e.m. P-values were
determined by unpaired, two-tailed Student’s t-test (c), NS, not significant.
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Express) with 10 µM of Y-27631 dihydrochloride for 15 min at 37 °C. The dis-
sociated prostate was washed once by topping up 10 ml with adDMEM/F12 (gibco)
and then centrifuged at 150 × g for 5 min. Twenty-thousand cells cells per drop
were plated in Matrigel (Corning Matrigel Nr. 356231). To overexpress SPOP
species and ΔERG genes, mouse prostate cells were virally infected by spinoculation
for 1 h at 600 × g at 32 °C and selected with puromycin. For the “organoid for-
mation assay,” 1.5 × 104 single cells were plated per well onto 40 µl of Matrigel on
day 1 and organoids were grown in “revised human prostate organoids medium” as
previously described43. Briefly, the medium included the following reagents:
adDMEM/F12 (gibco), glutaMAX (2mM), Pen-strep 100 u/ml, HEPES (10 mM),
B27 (1X), EGF (5 ng/ml), AB3-01 (500 nM), Noggin (100 ng/ml), R-Spondin 1
(500 ng/ml), DHT (1 nM), FGF-2 (5 ng/ml), FGF-10 (10 ng/ml), Prostaglandin E2
(1000 nM). The number of formed organoids that reached 100 μM of diameter was
counted on days 14 post-plating with cellSens software (Olympus). For the
Dose–Response experiment 1 × 104 mouse prostate cells were plated in 40 µl of
Matrigel and treated with vehicle (0.1% DMSO) or drug (SPOP-i) at the indicated
concentration for 7 days. Live/dead staining was performed using Calcein AM
(final concentration 1 µM) and Ethidium Homodimer I (EthD-1, final con-
centration (1.33 µM) dissolved in the medium for 1 h. GFP or RFP-positive
organoids were analyzed under a fluorescence microscope. The percentage of dead
organoids (RFP-positive) was normalized to the Etoposide-treated (positive con-
trol) organoids. The genetically engineered Mouse Prostate Organoids were derived
from PbCre;R26F133V 13.
Immunohistochemistry. Cytoblocks were prepared from the pellets of organoids
by adding plasma and thrombin in order to obtain a solid matrix. Once solidified,
the organoids were fixed in 10% formalin (Thermo Scientific, 5701) and embedded
in paraffin as normal tissue. Sections of 4 μm were used for IHC analyses and
hematoxylin and eosin (H&E) staining (Diapath, C0303) and (Diapath, C0363),
respectively. Once dried, the sections were treated with OTTIX plus solution
(Diapath, X0076) and OTTIX shaper solution (Diapath, X0096) to dewax and
rehydrate the sections. Antigen retrieval was performed using pH 6 solutions at
98 °C for 20 min. Next, the endogenous peroxidases and non-specific-binding sites
were blocked using 3% H2O2 (VWR chemicals, 23615.248) and Protein-Block
solution (DAKO Agilent technologies, X0909) respectively, for 10 min. Sections
were then stained for anti-p16 (ab211542, Abcam, 1:1200), anti-Ki67 (Clone SP6;
Lab Vision Corporation #RT-9106-R7, RTU) anti-Phospho-HP1y (Ser83)
Antibody (CST #2600, 1:200), anti-CK8 (ab,59400, Abcam), anti-CK5 (ab52635,
Abcam). IHC analyses were performed using the Imagescope software.
In vivo experiments. All animal experiments were carried out in male athymic
nude mice (Balb/c nu/nu, 6–8-weeks-old), NSG mice (NOD Scid Gamma, 6–8-
week-old), and NRG (NOD Rag gamma, 6–8-week-old) accordingly to protocol
approved by the Swiss Veterinary Authority (No. TI-14-2014, TI-38-2018, TI-39-
2018 and TI-42-2018). Patient-derived xenografts (PDX) LuCaP-147, −78, −35,
−23 were provided by Eva Corey (University of Washington) and maintained as
previously described46,47. Briefly, PDXs tumors were maintained by subcutaneous
implantation of matrigel-embedded tumor fragment (1–2-mmm average dia-
meter). In all, 2 × 106 VCaP cells, 5 × 106 LuCaP-147, LuCaP-23.1, LuCaP-35, and
LuCaP-78 were resuspended in 100 μl of PBS and Matrigel 1/1 and subcutaneously
injected into both of the dorsal flanks of the mice. Tumor growth was recorded
using a digital caliper, and tumor volumes were calculated using the formula (L x
W 2)/2, where L= length andW=width of tumor. For the testosterone propionate
(25 mg/kg) and SPOP inhibitor (SPOP-i, 50 mg/kg) treatment, the mice were
grouped randomly, and the treatment started when the mean tumor volume
reached 100 m3. Tumor volume and weight were measured two times per week.
Testosterone propionate was resuspended first in ethanol (150 mg/kg) and then in
Corn oil (Sigma) at a final concentration of 25 mg/kg. SPOP inhibitor was resus-
pended in Dulbecco’s PBS at a final concentration of 50 mg/kg. At the end of the
experiment, mice were euthanized, tumors extracted, and weighted. Testosterone
level was measured using the Human Testosterone ELISA Kit from Abcam
(ab174569). Mouse house ambient temperature was between 20 and 22 °C with
humidity between 50 and 65% and a dark/light cycle of 12 h each. In order to
recapitulate the levels of supraphysiological testosterone administrated in clinical
trials37, mice reaching at least three times the testosterone levels measured before
the treatment initiated were included in the depicted data.
Antibodies, immunoblotting, and immunoprecipitation. Antibodies used in
immunoblotting and immunoprecipitation assays were: anti-SPOP dilution 1:1000
(ab81163, Abcam), anti-TRIM24, dilution 1:1000 (Sc-271266, Santa Cruz), anti-ß-
ACTIN dilution 1:1000 (4967, Cell Signaling), anti-AR dilution 1:1000 (Sc-7305,
Santa Cruz), anti-GADPH dilution 1:1000 (Sc-47724, Santa Cruz), anti-ERG
dilution 1:1000 (Sc-271048, Santa Cruz), anti-α-Tubulin dilution 1:1000 (3873S,
Cell Signaling), anti-ZMYND11 dilution 1:1000 (NBP2-20960, Novus Biologicals),
anti-HA dilution 1:1000 (H3663, Sigma), anti-BRD2 dilution 1:1000 (A302-583A,
Bethyl Labs), anti-NCOA3 dilution 1:1000 (2126, Cell Signaling), anti-DEK dilu-
tion 1:1000 (610948, BDBioscience), anti-p21 dilution 1:1000 (2947S, Cell Signal-
ing), anti-c-MYC dilution 1:1000 (5605S, Cell Signaling), anti-HOXB13 dilution
1:1000 (Sc-28333, Santa Cruz), anti-PTEN dilution 1:1000 (9559, cell signaling),
anti-p21 dilution 1:1000 (ab188224, Abcam), anti-HOXB13 dilution 1:1000
(NBP2-43655, Novus biologicals), anti-GDF-15 dilution 1:1000 (27455-1-AP,
proteintech).
For immunoblotting, cells were washed with PBS and subsequently lysed in
RIPA buffer (Sigma) and sonicated. Protein concentration was determined using
the BCA reagent (ThermoFisher), the same amounts of protein were separated by
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Biorad)
and transferred onto polyvinylidene fluoride membrane (ThermoScientific). The
membrane was incubated for 1 h in 5% nonfat dry milk/TBS-T blocking buffer
followed by incubation with the primary antibody overnight at 4 °C. The
membrane was washed with TBS-T followed by incubation with horseradish
peroxidase-conjugated secondary antibody 1:5000 (W4028 or W4018, Promega).
To detect interactions of SPOP and ZMYND11, cells were lysed in 1 % NP40
buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP40) with 2x protease
inhibitor cocktail (Complete, Roche), sonicated, and 3 mg of lysate were incubated
overnight with 2 μg of anti-HA-tag or control mouse IgG antibody (sc-2025, Santa
Cruz Biotechnology) at 4 °C. Subsequently, antibodies were collected by 25 μl
protein A/G magnetic beads (88803, Fisher Scientific) for 2 h, followed by two
washing steps with 1% NP40 buffer. Proteins were eluted by adding 1x SDS-sample
buffer under reducing conditions at 95 °C for 5 min.
In vivo ubiquitylation assay. In all, 293T cells were transiently transfected with
indicated plasmids: pCW107-HA-ZMYND11-WT or HA-ZYMND11-DMT1/
DMT2 (2 μg), pCW107-SPOP-WT or SPOP-MT (2 μg), CMV-8x Ubi-His (2 μg).
Forty-two hours later, cells were treated with MG-132 (20 μM) or DMSO for
additional 7 h. Cells were then washed with PBS and collected by centrifugation. A
small number of cells was lysed in RIPA buffer and the rest in Buffer C (6 M
guanidine–HCL, 0.1 M Na2HPO4/NaH2PO4, 10 mM Imidazole, pH= 8). The
whole-cell extract was sonicated and incubated with 60 μl of Ni-NTA agarose
(Sigma) overnight at 4 °C. Next, Ni-NTA beads were washed once with Buffer C,
twice with Buffer D (1 volume of Buffer C: three volumes of Buffer E) and once
with Buffer E (25 mMTris-HCL, 20 mM Imidazole, pH= 6.8). Elution of bound
proteins was processed by boiling in 1x SDS loading buffer containing 300 mM
Imidazole. Samples were loaded, separated by SDS-PAGE, and detected by
immunoblotting.
Fig. 10 Schematic representation of the proposed model for the aversive
relationship between mutant SPOP and ERG in prostate cancer. On the
left side, SPOP mutant prostate cancer tumorigenesis is depicted. SPOP
mutant tumors impair the degradation of substrate proteins such as AR
activators (e.g, TRIM24) and ZMIND11, which ultimately triggers the AR
pathway and dampens the ERG signaling. In this context, SPOP mutant
tumors are more susceptible to ADT therapy. On the right side, TMPRSS2-
ERG mutant tumorigenesis is depicted. ERG binds to the promoter of wild-
type SPOP, upregulating its protein expression. Consequently, AR
activators and ZMYND11 substrate proteins get degraded, leading to the
AR pathway downregulation and unleashing the ERG signaling pathway.
TMPRSS2-ERG mutant tumors are thus sensitive to high-dose androgen
therapy or SPOP inhibition.
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Gene expression studies. RNA was extracted using the RNeasy kit (Qiagen) and
processed by Kapa SybrFAST one-Step quantitative reverse transcription PCR
(qRT-PCR) kit according to the manufacturer’s instructions. qRT-PCR was
undertaken on an Applied Biosystems StepOnePlus System. The target mRNA
expression was quantified using ∆∆Ct method and normalized to Actin expression.
The primers used in the study can be found in Supplementary Table 1.
RNA-Seq of VCaP, LNCaP, and LuCaP cells. RNA sequencing for all experiments
involving LuCaP xenografts, VCaP and LNCaP cells was performed at the Institute
of Oncology Research using Next Ultra II Directional RNA Library Prep Kit for
Illumina and sequenced on the Illumina NextSeq500 with single-end, 75 base pair
long reads. The overall quality of sequencing reads was evaluated using various
tools, namely FastQC (Andrews S., 2010), RSeQC48, AfterQC49 and Qualimap50.
Sequence alignments to the reference human genome (GRCh38) was performed
using STAR51 (v.2.5.2a). Gene-expression was quantified at the gene level by using
the comprehensive annotations made available by Gencode52. Specifically, we used
v27 release of the Gene Transfer File (GTF). Raw-counts were further processed in
the R Statistical environment and downstream differential expression analysis was
performed using the DESeq253 pipeline.
Genes being expressed at very low levels were automatically filtered out through
the Independent Filtering feature embedded in DESeq2 (alpha= 0.05). Differential
expression results were ranked according to the computed Wald-statistics values.
Subsequently, gene-set enrichment testing was performed using Camera54 pre-
ranked (inter-gene correlation equal to 0.1, parametric test procedure). Statistical
enrichments were assessed for gene-sets belonging to the Hallmark collection,
which is curated by the Molecular Signature DataBase55,56 (MSigDB), and for
custom ERG and DHT-specific gene-signatures. All enrichments were corrected for
multiple testing using Benjamini and Hochberg FDR-adjusted P-value.
Identification of ERG and AR-related gene signatures. We retrieved RNA-seq
data from GEO Dataset GSE8365216 to identify transcriptional perturbations in
VCaP cells following treatment with DHT or following ERG silencing. To this
purpose, we completely reprocessed samples SRR3713255-57, SRR3713267-72
using STAR and DESeq2 as previously described for VCaP cells. In addition, to
identify direct targets, we integrated information relative to AR and ERG
chromatin-binding sites, which we derived from GEO Dataset GSE2895027. To
maximize the number of peaks and reduce false negatives, we merged experiments
performed at different time points, namely 2 h and 18 h after DHT exposure. De-
multiplexed reads were aligned to hg38 release of the human reference genome
using bwa-mem57 (0.7.15). MACS58 (v.2.1.0) was used to perform peak calling
procedure using a cutoff FDR q-value of 0.01 and a mappable genome size opti-
mized for hg38 equal to 2.9 gigabases. Downstream analysis was performed in R
statistical environment. We identified binding sites overlapping promoters by using
bedtools59.
Promoters were defined as DNA regions ranging from 1500 bp upstream to 500
bp downstream of Transcription Start Sites (TSSs).
To discriminate between ERG- and AR-specific transcriptional responses we
stratified genes into three main classes: genes whose promoter regions are bound by
AR but not by ERG, genes whose promoters are bound by ERG but not by AR, and
finally, genes whose promoters are co-bound by both AR and ERG. AR bound only
genes were further subdivided into two sets, those being significantly (FDR < 0.05)
induced following DHT treatment and those being significantly repressed. A
similar approach was applied to ERG bound only genes, where genes were
subdivided into ERG-induced and ERG-repressed gene-sets, if they were
respectively down or upregulated following ERG silencing. To be more stringent in
the definition of AR-specific and ERG-specific signatures, we excluded genes from
the ERG-induced set that were also significantly upregulated following DHT
treatment, vice-versa we excluded ERG-repressed genes that were significantly
downregulated following DHT treatment. The same criteria were applied for DHT-
specific gene-sets. Finally, defined an additional gene-set (DHT-induced/ERG-
repressed) consisting of genes being co-bound by AR and ERG in their promoter
region, which were significantly upregulated following DHT treatment but also
significantly upregulated following ERG silencing. The overlap between custom
derived gene-signatures and the most represented Hallmark’s gene-sets was
assessed using GeneOverlap R package60. Two-dimensional network visualization
was generated with Cytoscape.61
Gene-set testing and RNA-Seq data processing of clinical samples. Publicly
available RNA-Seq data for primary prostate cancer were obtained from The Caner
Genome Atlas3 (TCGA) database and retrieved from Genomics Data Commons
(GDC) in the form of gene-centric raw counts, using TCGAbiolinks package62. We
selected individuals characterized by either SPOP or ERG fusion and a third group
defined as “others,” which includes all remaining samples, excluding those patients
exhibiting any other ETS-rearrangement. Differential expression and gene-set
enrichment between samples harboring ERG fusions and SPOP-mutations were
performed using DESeq2 and Camera (pre-ranked) as previously described for
prostate cancer cells. Single-sample gene-set enrichment analysis (GSVA63 pack-
age) was applied to measure, for each individual patient, the overall activity of the
custom gene-sets that were previously generated in VCaP cells. Following
differential expression analysis between ERG-rearranged and SPOP mutant pri-
mary tumors, we defined two gene-sets consisting of SPOP-upregulated (n= 443,
log2FC > 1, FDR < 0.05) and ERG-upregulated (n= 359, log2FC > 1, FDR <
0.05) genes.
PolyA+ RNASeq data for metastatic prostate cancer were obtained from SU2C
cohort64. Normalized RPKM values, retrieved through cBioportal, were log
transformed and patient’s categorization (SPOP/ERG/OTHER) was performed in
the same manner as for primary tumors. To evaluate whether transcriptional
differences between ERG-rearranged and SPOP-mutant individuals were also
conserved in the CRPC setting, we quantified the above mentioned SPOP-
upregulated/ERG-upregulated signatures in the SU2C 2019 cohort, using single-
sample gene-set enrichment analysis. The obtained ssGSEA scores were scaled in a
range between −1 and 1 (SPOP-Upregulated) and between 1 and −1 (ERG-
upregulated, inverted). Subsequently, we averaged these rescaled values in order to
obtain an aggregate score.
Circular representation of interactions between gene-sets. Chord diagrams
were generated using circlize65 package in R statistical environment.
Strings, whose thickness is proportional to the number of shared elements,
represent common genes between sets.
ZMYND11 ChIP-seq in VCaP cells. ChIP-seq using an anti-ZMYND11 antibody
(NBP2-20960, Novus Biologicals) was performed in VCaP cells, overexpressing
either wild-type SPOP or mutant SPOP harboring Y87C point mutation. Briefly, to
isolate chromatin, cells (120.000.000 per IP) were cross-linked using 1% For-
maldehyde cross-link protein-DNA complexes, and cross-linking was terminated
by the addition of 1/10 volume 1.25 M glycine for 5 min at room temperature
followed by cell lysis and sonication, resulting in an average chromatin fragment
size of 200 bp. Samples lysis was performed as previously described using MNase
enzyme 1000 gel units= 1 µL66. After adding the MNase sonication buffer, the
samples were sonicated for 30 cycles, 30 s ON and 30 s OFF at high voltage. ChIP
and input DNA (50 ng) were used for indexed library preparation using NEBNext
Ultra II DNA Library Prep kit and subjected to 75 bp single-end sequencing on the
Illumina NextSeq500. All procedures were performed at the Institute of Oncology
Research. De-multiplexed reads were aligned to hg38 release of the human refer-
ence genome using bwa-mem57 (0.7.15). MACS58 (v.2.1.0) was used to perform
peak calling procedure using a cutoff FDR q-value of 0.01 and a mappable genome
size optimized for hg38 equal to 2.9 gigabases. Downstream analysis was performed
in R statistical environment. ChIPseeker67 was used to annotate peaks and to
represent the distribution of ZMYND11-binding sites relative to Transcription
Start Sites (TSSs). The R package chipenrich68 was subsequently used to determine
enrichment or depletion of ZMYND11 peaks in regions surrounding TSSs of genes
that are included in Hallmarks or custom gene-set collections. Surrounding regions
were defined as ranging from 5 kb upstream to 5 kb downstream of their TSSs
(locusdef= 5 kb), which is in line with the overall behavior of ZMYND11-binding
sites around TSSs (Supplementary Fig. 6f-g).
Identification of AR-binding sites in primary prostate cancer specimen. Pub-
licly available ChIP-Seq data were retrieved from GSE1207383. ChIP-seq data were
reprocessed as described for ZMYND11 samples. The differential binding affinity
of AR between ERG-rearranged and SPOP-mutant tumors was performed using
DiffBind (Stark R and Brown G, 2011).
Frequency of SPOP mutations across patients’ cohorts. We defined the per-
centage of SPOP-mutant and TMPRSS2-ERG-positive tumors across different
patients’ cohorts originating from multiple sources. Patients with primary/loco-
regional prostate tumors were derived from TCGA and MSK-IMPACT Clinical
Sequencing cohorts36. Patients with tumor-progression (non-castrate) were derived
from MSK-IMPACT and TCGA cohorts, by including from the latter only indi-
viduals that showed tumor-progression based on survival information. Castration-
resistant prostate cancer patients were retrieved from MSK-IMPACT, Beltran
et al.69 and from the SU2C64.datasets. Neuroendocrine prostate cancer samples
were retrieved from the SU2C cohort (samples annotated with neuroendocrine
features) and from Beltran et al.69. The total number of SPOP-mutant and
TMPRSS2-ERG tumors was determined based on the individual studies’ clinical
annotations and integrated with fusion information from TCGA Fusion Gene
Database (www.tumorfusions.org). Survival analysis was performed in R statistical
environment using the TCGA and MSK-IMPACT clinical sequencing cohort.
Quantitative liquid chromatography–mass spectrometry (LC-MS/MS). In
solution digestion VCaP cell pellets were lysed at 4 °C in 8 M urea, 50 mM Tris-
HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 2 µg/µl aprotinin (Sigma-Aldrich), 10 µg/
µl leupeptin (Roche), and 1 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma).
Protein concentration was determined using a bicinchoninic acid (BCA) protein
assay (Pierce). Proteins were reduced with 5 mM (DTT) for 45 min at room
temperature (RT), followed by alkylation with 10 mM iodoacetamide for 30 min at
room temperature in the dark. The urea concentration was reduced to 2M using
50 mM Tris-HCl, pH 8. Samples were digested for 2 h at 25 °C with endoproteinase
Lys-C (Wako Laboratories) at an enzyme-to-substrate ratio of 1:50. Samples were
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subsequently digested overnight at 25 °C with sequencing grade trypsin (Promega)
at an enzyme-to-substrate ratio of 1:50. Following overnight digestion, samples
were acidified to a final concentration of 1% formic acid.
Peptide samples were desalted on a 100 mg tC18 Sep-Pak SPE cartridge
(Waters). Cartridges were conditioned with 1 ml of 100% MeCN, 1 ml of 50%
MeCN/0.1% FA, and 4x with 1 ml of 0.1% TFA. The sample was loaded, and
washed 3x with 1 ml of 0.1% TFA, 1x with 1 ml of 1% FA, and eluted 2x with 600 µl
of 50% MeCN/0.1% FA.
TMT labeling of peptides. Peptides were labeled with TMT 10-plex isobaric mass
tagging reagents (Thermo Fisher Scientific). Each TMT reagent was resuspended in
41 µL of MeCN. Peptides were resuspended in 100 µL of 50 mM HEPES and
combined with TMT reagent. Samples were incubated at RT for 1 h while shaking.
The TMT reaction was quenched with 8 µL of 5% hydroxylamine at RT for 15 min
with shaking. TMT labeled samples were combined, dried to completion, recon-
stituted in 100 µL of 0.1% FA, and desalted on StageTips or 100 mg SepPak col-
umns as described above.
Basic reverse phase (bRP) fractionation. The TMT labeled samples were frac-
tionated using offline high pH reversed-phase chromatography (bRP) as previously
described70. Samples were fractionated using Zorbax 300 Extend C18 column
(4.6 × 250 mm, 300 Å, 5 μm, Agilent) on an Agilent 1100 series high-pressure liquid
chromatography (HPLC) system. Samples were reconstituted in 900 µL of 4.5 mM
ammonium formate (pH 10) in 2% (vol/vol) acetonitrile (MeCN) (bRP solvent A).
Samples were injected with Solvent A at a flow rate of 1 ml/min and separated
using a 96 min gradient. The gradient consisted of an initial increase to 16% solvent
B (90% MeCN, 5 mM ammonium formate, pH 10), followed by 60 min linear
gradient from 16% solvent B to 40% B and successive ramps to 44% and 60% at a
flow rate of 1 ml/min. Fractions were collected in a 96-deep well plate (GE
Healthcare) and pooled in a non-contiguous manner into final 24 proteome
fractions. Pooled fractions were dried to completeness using a SpeedVac
concentrator.
Liquid chromatography and mass spectrometry. Desalted peptides were resus-
pended in 3% MeCN/0.1% FA and analyzed by online nanoflow liquid
chromatography–tandem mass spectrometry (LC-MS/MS) using Q-Exactive plus
mass spectrometer (Thermo Fisher Scientific) coupled online to a Proxeon Easy-
nLC 1200 as previously described70. Briefly, 1 µg of each sample was loaded onto a
microcapillary column (360 μm outer diameter × 75 μm inner diameter) containing
an integrated electrospray emitter tip (10 μm), packed to ~22 cm with ReproSil-Pur
C18-AQ 1.9 μm beads (Dr. Maisch GmbH) and heated to 50 °C. Samples were
analyzed with 110 min LC-MS method. The 110 min method contained a mobile
phase with a flow rate of 200 nl/min, comprises 3% acetonitrile/0.1% formic acid
(Solvent A) and 90% acetonitrile/0.1% formic acid (Solvent B), with the following
gradient profile: (min:%B) 0:2; 1:6; 85:30; 94:60; 95:90; 100:90; 101:50; 110:50 (the
last two steps at 500 nl/min flow rate). The Q-Exactive plus MS was operated in the
data-dependent mode acquiring HCD MS/MS scans (r= 35,000) after each
MS1 scan (r= 70,000) on the 12 most abundant precursor ions using an MS1
target of 3 × 106 and an MS2 target of 5 × 104. The maximum ion time utilized for
MS/MS scans was 120 ms; the HCD-normalized collision energy was set to 30; the
dynamic exclusion time was set to 20 s, isotope exclusion function was enabled, and
peptide match function was set to preferred. Charge exclusion was enabled for
charge states that were unassigned, 1 and >6.
MS data analysis. All data were analyzed using Spectrum Mill software package v
6.1 pre-release (Agilent Technologies). Similar MS/MS spectra acquired on the
same precursor m/z within+ /− 60 s were merged. MS/MS spectra were excluded
from searching if they were not within the precursor MH+ range of 750–4000 Da
or if they failed the quality filter by not having a sequence tag length >0. MS/MS
spectra were searched against UniProt human database. All spectra were allowed
+ /− 20 ppm mass tolerance for precursor and product ions, 30% minimum
matched peak intensity, and “trypsin allow P” enzyme specificity with up to 4
missed cleavages. The fixed modifications were carbamidomethylation at cysteine,
and TMT at N-termini and internal lysine residues. Variable modifications
included oxidized methionine and N-terminal protein acetylation. Individual
spectra were automatically designated as confidently assigned using the Spectrum
Mill autovalidation module. Specifically, a target-decoy-based false-discovery rate
(FDR) scoring threshold criteria via a two-step auto threshold strategy at the
spectral and protein levels was used. First, peptide mode was set to allow automatic
variable range precursor mass filtering with score thresholds optimized to yield a
spectral level FDR of 1%. A protein polishing autovalidation was applied to further
filter the peptide spectrum matches using a target protein-level FDR threshold of 0.
Following autovalidation, a protein–protein comparison table was generated, which
contained experimental ratios. For all experiments, non-human contaminants and
reversed hits were removed. Furthermore, data were filtered to only consider
proteins with two or more unique peptides and was median normalized.
Statistical analysis. GraphPad Prism version 8.3 (GraphPad Software) was used
for statistical analysis. Data are depicted as mean+ s.e.m. unless otherwise
specified. The number of independent experiments or mice used is indicated in
each figure legends. Unpaired Student’s t-test was used for comparisons between
two groups, one-way analysis of variance (ANOVA) with multiple comparisons for
two groups or more, and two-way ANOVA with multiple comparisons for repeated
measurements. Multiple comparison tests were corrected by controlling the false-
discovery rate (FDR) using Benjamini and Hochberg’s method. Correlation ana-
lyses were performed using Pearson correlation coefficients.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The original mass spectra have been deposited in the public proteomics repository
MassIVE (identifiers MSV000082915) and are accessible at https://massive.ucsd.edu/
ProteoSAFe/dataset.jsp?task=462f4fc4ab6243ac893e07ca35bd4ae3. RNA-Seq data
generated have been deposited in the ArrayExpress database at EMBL-EBI and are
accessible at: overexpression or knockdown of mutant- or wild type SPOP in VCaP
prostate cancer cells https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-7165/.
Overexpression of either mutant- or wild type SPOP in presence/absence of ΔERG in
LNCaP prostate cancer cells https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-
7170/. Overexpression of the SPOP-substrate ZMYND11 in VCaP cells https://www.ebi.
ac.uk/arrayexpress/experiments/E-MTAB-7173/. CHiP-Seq data generated have been
deposited in the ArrayExpress database at EMBL-EBI and are accessible at: identification
of ZMYND11-binding sites in VCaP cells with stable overexpression of either mutant
(Y87C) or wild-type SPOP https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-
7174/. Source data are provided with this paper.
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